{"id":10061,"date":"2026-02-24T06:42:08","date_gmt":"2026-02-24T12:42:08","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10061"},"modified":"2026-02-24T06:49:19","modified_gmt":"2026-02-24T12:49:19","slug":"nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306b\u3088\u308b\u4e8b\u5f8c\u81e8\u5e8a\u89e3\u6790\u7d50\u679c\u304c\u30012026\u5e74\u9ec4\u6591\u5b66\u4f1a\u5e74\u6b21\u7dcf\u4f1a\u3067\u767a\u8868\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3059\u3002"},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u30af\u30ea\u30b9\u30c6\u30a3\u30f3\u30fbN\u30fb\u30b1\u30a4\u535a\u58eb\u306f\u3001MCO-010\u5149\u907a\u4f1d\u5b66\u7684\u907a\u4f1d\u5b50\u6cbb\u7642\u5f8c\u306e\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u60a3\u8005\u306b\u304a\u3051\u308b\u6700\u826f\u306e\u8ee2\u5e30\u306b\u95a2\u9023\u3059\u308b\u60a3\u8005\u304a\u3088\u3073\u75be\u60a3\u7279\u6027\u3092\u7279\u5b9a\u3059\u308b\u30013\u5e74\u9593\u306eRESTORE\u304a\u3088\u3073REMAIN\u30c7\u30fc\u30bf\u306e\u591a\u5909\u91cf\u89e3\u6790\u3092\u767a\u8868\u3057\u307e\u3059\u3002<\/strong><\/em><\/h3>

\u30c0\u30e9\u30b9<\/span>,\u00a02026\u5e742\u670824\u65e5<\/span>\u00a0 \u2014 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e<\/a>, \u7db2\u819c\u5909\u6027\u306b\u3088\u308b\u5149\u53d7\u5bb9\u4f53\u55aa\u5931\u304a\u3088\u3073\u8996\u899a\u969c\u5bb3\u306e\u60a3\u8005\u5411\u3051\u306b\u3001\u75be\u60a3\u3092\u554f\u308f\u306a\u3044\u65b0\u898f\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u304a\u3088\u3073\u5546\u696d\u5316\u306b\u53d6\u308a\u7d44\u3080\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308b \u306f\u672c\u65e5\u3001\u540c\u793e\u306e\u4e3b\u8981\u306a\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3067\u3042\u308b MCO-010 \u306e\u65b0\u305f\u306a\u4e8b\u5f8c\u81e8\u5e8a\u89e3\u6790\u304c\u3001\u00a02026\u5e74\u9ec4\u6591\u5b66\u4f1a\u5e74\u6b21\u7dcf\u4f1a\u00a0<\/b>2026\u5e742\u670825\u65e5\uff5e28\u65e5\u306b\u958b\u50ac\u3055\u308c\u308b<\/b>\u00a0\u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30b5\u30f3\u30c7\u30a3\u30a8\u30b4<\/b>.<\/p>

\u30af\u30ea\u30b9\u30c6\u30a3\u30f3\u30fbN\u30fb\u30b1\u30a4\u533b\u5e2b.<\/a><\/b>, \u30d5\u30ed\u30ea\u30c0\u5dde\u30b2\u30a4\u30f3\u30ba\u30d3\u30eb\u306b\u3042\u308bVitreoretinal Associates\u306e\u81e8\u5e8a\u7814\u7a76\u304a\u3088\u3073\u7db2\u819c\u907a\u4f1d\u5b66\u30c7\u30a3\u30ec\u30af\u30bf\u30fc\u3067\u3042\u308b[\u6c0f\u540d]\u306f\u30013\u5e74\u9593\u306e\u7121\u4f5c\u70ba\u5316\u7b2c2b\/3\u76f8\u8a66\u9a13\u306e\u9577\u671f\u8ffd\u8de1\u8abf\u67fb\u304b\u3089\u5f97\u3089\u308c\u305f\u65b0\u305f\u306a\u89e3\u6790\u7d50\u679c\u3092\u767a\u8868\u3057\u3001\u6700\u826f\u306e\u7d50\u679c\u306b\u95a2\u9023\u3059\u308b\u60a3\u8005\u304a\u3088\u3073\u75be\u60a3\u306e\u7279\u5fb4\u3092\u691c\u8a3c\u3057\u307e\u3059\u3002\u3053\u308c\u3089\u306e\u30c7\u30fc\u30bf\u304c\u767a\u8868\u3055\u308c\u308b\u306e\u306f\u4eca\u56de\u304c\u521d\u3081\u3066\u3067\u3042\u308a\u3001\u91cd\u5ea6\u306e\u8996\u529b\u4f4e\u4e0b\u3092\u4f34\u3046\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u60a3\u8005\u306b\u5bfe\u3059\u308bMCO-010\u306e1\u56de\u6295\u4e0e\u306e\u52b9\u679c\u3092\u7406\u89e3\u3059\u308b\u305f\u3081\u306e\u3001\u3088\u308a\u5145\u5b9f\u3057\u305f\u67a0\u7d44\u307f\u3092\u81e8\u5e8a\u533b\u306b\u63d0\u4f9b\u3057\u307e\u3059\u3002.<\/p>

\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u306e\u8a73\u7d30\uff1a<\/b><\/p>

\u30d7\u30ec\u30bc\u30f3\u30bf\u30fc\uff1a\u00a0<\/b>\u30af\u30ea\u30b9\u30c6\u30a3\u30f3\u30fbN\u30fb\u30b1\u30a4\u533b\u5e2b.
\u30bf\u30a4\u30c8\u30eb\uff1a\u00a0<\/b>\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u304a\u3051\u308b\u8996\u529b\u6539\u5584\u52b9\u679c\uff1aMCO-010\u5149\u907a\u4f1d\u5b66\u7684\u907a\u4f1d\u5b50\u6cbb\u7642\u306e3\u5e74\u9593\u306eRESTORE\u304a\u3088\u3073REMAIN\u30c7\u30fc\u30bf\u306b\u57fa\u3065\u304f\u591a\u5909\u91cf\u89e3\u6790
<\/i>\u30bb\u30c3\u30b7\u30e7\u30f3\uff1a\u00a0<\/b>\u907a\u4f1d\u6027\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fcI\uff1a\u81e8\u5e8a\u8a66\u9a13\u3068\u305d\u306e\u5148
Date & Time:\u00a0<\/b>2\u670827\u65e5\uff08\u91d1\uff09\u5348\u524d7\u664230\u5206\uff5e\u5348\u524d7\u664235\u5206<\/p>

“These analyses are an important next step in helping to understand the Phase 3 clinical trial data of MCO-010 in retinitis pigmentosa,” said Dr. Kay.<\/b>\u00a0“By examining the characteristics of patients who had the best outcomes across three years of follow-up in RESTORE and REMAIN, we can begin to understand how the therapy can be used in patients in the real world, if approved.”<\/p>

“Dr. Kay’s multivariant analyses add a clinically significant dimension to what is already a landmark dataset,” said\u00a0<\/b>\u30b5\u30df\u30e5\u30a8\u30eb\u30fb\u30d0\u30ed\u30f3\u533b\u5e2b.<\/a><\/b>, \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306e\u6700\u9ad8\u533b\u7642\u8cac\u4efb\u8005\u3002.<\/b>\u00a0“We are proud to present this work at the Macula Society Annual Meeting, where leading retinal specialists will be able to engage directly with the findings as we continue our rolling BLA for MCO-010 \u2013 potentially offering the first approved therapy for patients with retinitis pigmentosa having severe vision loss.”<\/p>

MCO\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306b\u3064\u3044\u3066
<\/b>MCO\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\u3001\u5730\u56f3\u72b6\u840e\u7e2e\u75c7\uff08GA\uff09\u306a\u3069\u306e\u5149\u53d7\u5bb9\u4f53\u5909\u6027\u75c7\u60a3\u8005\u306e\u8996\u529b\u56de\u5fa9\u3092\u76ee\u7684\u3068\u3057\u305f\u3001\u75be\u60a3\u3092\u554f\u308f\u306a\u3044\u5358\u56de\u6295\u4e0e\u306e\u785d\u5b50\u4f53\u5185\u6cbb\u7642\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002MCO\u306f\u3001\u9ad8\u5bc6\u5ea6\u306e\u53cc\u6975\u7db2\u819c\u7d30\u80de\u3092\u6d3b\u6027\u5316\u3057\u3066\u5149\u611f\u53d7\u6027\u3092\u6301\u305f\u305b\u308b\u3053\u3068\u3067\u3001\u5149\u53d7\u5bb9\u4f53\u6b7b\u5f8c\u306b\u6b8b\u5b58\u3059\u308b\u8996\u899a\u56de\u8def\u3092\u6d3b\u7528\u3057\u307e\u3059\u3002MCO\u6cbb\u7642\u306f\u3001\u907a\u4f1d\u5b50\u691c\u67fb\u3001\u4fb5\u8972\u7684\u306a\u624b\u8853\u3001\u307e\u305f\u306f\u7e70\u308a\u8fd4\u3057\u6295\u4e0e\u3092\u5fc5\u8981\u3068\u3057\u306a\u3044\u305f\u3081\u3001\u65e2\u5b58\u306e\u7db2\u819c\u8a3a\u7642\u30ef\u30fc\u30af\u30d5\u30ed\u30fc\u5185\u3067\u5e45\u5e83\u3044\u60a3\u8005\u306b\u9069\u7528\u53ef\u80fd\u3067\u3059\u3002.<\/p>

\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306b\u3064\u3044\u3066
<\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306f\u3001\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u3088\u308a\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u3001\u75be\u60a3\u3092\u554f\u308f\u306a\u3044\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\uff08NCT04945772<\/a>\uff09\u3001FDA\u3078\u306eBLA\u7533\u8acb\u306f\u7d99\u7d9a\u7684\u306b\u884c\u308f\u308c\u3066\u3044\u307e\u3059\u3002\u627f\u8a8d\u3055\u308c\u308c\u3070\u3001MCO-010\u306f\u907a\u4f1d\u5b50\u691c\u67fb\u3092\u5fc5\u8981\u3068\u305b\u305a\u3001\u8a3a\u7642\u6240\u30671\u56de\u6ce8\u5c04\u3059\u308b\u3060\u3051\u3067\u6295\u4e0e\u3067\u304d\u308b\u305f\u3081\u3001RP\u60a3\u8005\u306e\u6a19\u6e96\u6cbb\u7642\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u540c\u793e\u306f\u307e\u305f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\uff08NCT05417126<\/a>\uff09\u3092\u958b\u59cb\u3057\u3001\u00a0\u30d5\u30a7\u30fc\u30ba3\u767b\u9332\u8a66\u9a13<\/a>\u00a02026\u5e74\u306b\u958b\u59cb\u4e88\u5b9a\u3067\u3059\u3002MCO-010\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3068\u30b9\u30bf\u30d5\u30a3\u30f3\u30fb\u30c0\u30a4\u30a2\u30e2\u30f3\u30c9\u75c7\uff08SD\uff09\u306e\u4e21\u65b9\u3067FDA\u306e\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u304a\u3088\u3073\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u304a\u308a\u3001SD\u306b\u3064\u3044\u3066\u306fRMAT\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001\u975e\u75c7\u5019\u6027\u304a\u3088\u3073\u75c7\u5019\u6027\u306e\u687f\u4f53\u30fb\u9310\u4f53\u512a\u4f4d\u6027\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u3001\u9ec4\u6591\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u3092\u5bfe\u8c61\u3068\u3059\u308bEMA\u306e\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002MCO-010\u306f\u3001\u65e5\u672c\u3067\u306f\u539a\u751f\u52b4\u50cd\u7701\u304b\u3089\u5148\u99c6\u533b\u85ac\u54c1\u304a\u3088\u3073\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u306e\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u5730\u7406\u7684\u840e\u7e2e\u75c7\uff08GA\uff09\u306b\u304a\u3051\u308bMCO\u306e\u7b2c2\u76f8\u30d7\u30ed\u30b0\u30e9\u30e0\u30822026\u5e74\u306b\u958b\u59cb\u4e88\u5b9a\u3067\u3059\u3002IND\u7533\u8acb\u6e96\u5099\u4e2d\u306e\u305d\u306e\u4ed6\u306e\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u306f\u3001\u30ec\u30fc\u30d0\u30fc\u5148\u5929\u6027\u9ed2\u5185\u969c\uff08LCA\uff09\u304c\u3042\u308a\u307e\u3059\u3002.<\/p>

\u63a5\u89e6\uff1a
<\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e
(817) 857-1186
PR@nanostherapeutics.com<\/a><\/p>

\u51fa\u5178 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Dr. Christine N. Kay to Present Multivariant Analysis of 3-Year RESTORE and REMAIN Data,\u00a0Identifying Patient and Disease Characteristics Associated with Best Outcomes in Retinitis Pigmentosa Patients Following MCO-010 Optogenetic Gene Therapy DALLAS,\u00a0Feb. 24, 2026\u00a0 — Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration,\u00a0today announced that new post-hoc clinical analyses from its lead optogenetic therapy, MCO-010, will be featured at the\u00a02026 Macula Society Annual Meeting\u00a0taking place February 25-28, 2026 in\u00a0San Diego, CA. Christine N. Kay, M.D., Director of Clinical Research and Retinal Genetics, Vitreoretinal Associates in Gainesville, FL, will present new analyses from […]<\/p>\n","protected":false},"author":1,"featured_media":10062,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10061","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T12:42:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T12:49:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting\",\"datePublished\":\"2026-02-24T12:42:08+00:00\",\"dateModified\":\"2026-02-24T12:49:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/\"},\"wordCount\":625,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_2026_Macula-Society_REV3.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/\",\"name\":\"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_2026_Macula-Society_REV3.jpg\",\"datePublished\":\"2026-02-24T12:42:08+00:00\",\"dateModified\":\"2026-02-24T12:49:19+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_2026_Macula-Society_REV3.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_2026_Macula-Society_REV3.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306b\u3088\u308b\u4e8b\u5f8c\u81e8\u5e8a\u89e3\u6790\u7d50\u679c\u304c\u30012026\u5e74\u9ec4\u6591\u5b66\u4f1a\u5e74\u6b21\u7dcf\u4f1a\u3067\u767a\u8868\u3055\u308c\u308b\u4e88\u5b9a - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-02-24T12:42:08+00:00","article_modified_time":"2026-02-24T12:49:19+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Wilson PJ","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"3\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting","datePublished":"2026-02-24T12:42:08+00:00","dateModified":"2026-02-24T12:49:19+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/"},"wordCount":625,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_2026_Macula-Society_REV3.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/","url":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306b\u3088\u308b\u4e8b\u5f8c\u81e8\u5e8a\u89e3\u6790\u7d50\u679c\u304c\u30012026\u5e74\u9ec4\u6591\u5b66\u4f1a\u5e74\u6b21\u7dcf\u4f1a\u3067\u767a\u8868\u3055\u308c\u308b\u4e88\u5b9a - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_2026_Macula-Society_REV3.jpg","datePublished":"2026-02-24T12:42:08+00:00","dateModified":"2026-02-24T12:49:19+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_2026_Macula-Society_REV3.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_2026_Macula-Society_REV3.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"\u30a6\u30a3\u30eb\u30bd\u30f3 PJ"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=10061"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10061\/revisions"}],"predecessor-version":[{"id":10066,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10061\/revisions\/10066"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/10062"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=10061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=10061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=10061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}